stockrowPalvella Therapeutics, Inc.
PVLA Healthcare Biotechnology
Palvella Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.9 million.
- EPS
- −76.7%
- Free cash flow
- −136.4%
Quarter to June 2026, against a year earlier
Follow PVLA
Alert me
Palvella Therapeutics, Inc. (PVLA) Return on equity
Palvella Therapeutics, Inc.'s return on equity over the twelve months to 30 June 2026 was −46.6%, up 45.5 percentage points from fiscal 2025 (−92.1%). Over the past ten years it has ranged from −111.9% (fiscal 2021) to 293.6% (fiscal 2024); the current reading is higher than 36% of that period. That is above the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −92.1% | (385.70) |
| FY2024 | 293.6% | 370.56 |
| FY2023 | −77.0% | 7.62 |
| FY2022 | −84.6% | 27.27 |
| FY2021 | −111.9% | (21.46) |
| FY2020 | −90.4% | (28.39) |
| FY2019 | −62.0% | 41.99 |
| FY2018 | −104.0% | (7.95) |
| FY2017 | −96.0% | (15.13) |
| FY2016 | −80.9% | (23.69) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| BHVN Biohaven Ltd. compare | 940.5% |
| AUPH Aurinia Pharmaceuticals Inc compare | 61.4% |
| ADMA ADMA Biologics Inc compare | 42.0% |
| VCEL Vericel Corporation compare | 9.44% |
| CLDX Celldex Therapeutics, Inc. compare | −43.9% |
| PVLA Palvella Therapeutics, Inc. | −46.6% |
| IMNM Immunome, Inc. compare | −64.0% |
| PHVS Pharvaris N.V. compare | −71.5% |
| VERA Vera Therapeutics, Inc. compare | −91.8% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on PVLA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement